Today was relationship building with subject matter expertsThe most important outcome of today's event are the new and hopefully enduring relationships that are formed. The key targets are the subject matter experts and key opinion leaders, foremost in the investment community, and secondarily with media.
There are no shortage of bio-health technology advisors and analysts. Although I highly doubt those with the banks, insurance and pension funds would have an interest in TLT at this stage. Instead, Theralase must hone its pitch to the smaller independents.
Should TLT ever achieve a billion dollar valuation, I would expect the big institutions would start paying attention.